3869 completed, 1228 recruiting, 1072 terminated, 917 unknown. 3402 Phase 2, 2836 Phase 1, 1020 Not applicable, 502 Phase 3, 253 Early Phase 1.
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas RNS System Implantation - Glioma, Glioma Intracranial | Not applicable | Not yet recruiting | Medical College of Wisconsin | 3 | 2028-08-01 | 2026-10-13 |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma | Phase 1 | Not yet recruiting | Universität Münster | 30 | 2027-10-01 | 2026-10-27 |
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Residual IDH1-Mutant Tumor Cell Quantification Study UR-ddPCR - Glioma | Not applicable | Not yet recruiting | NYU Langone Health | 105 | 2027-08-01 | 2026-09-29 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| DLL3 CAR-T Therapy Targeting Brain Tumors 4SCAR DLL3 T cells - Glioblastoma of Cerebellum | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-09-01 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors [F-18]MeFAMP PET - Healthy Volunteers, Recurrent Glioma | Early Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 28 | 2027-04-01 | 2026-08-20 |
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
| Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2 | Phase 3 | Not yet recruiting | Nuvation Bio Inc. | 140 | 2027-03-01 | 2026-07-17 |
| Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study Safusidenib - Glioma : Oligodendroglioma or Astrocytoma | Phase 2 | Not yet recruiting | University of Zurich | 20 | 2027-03-01 | 2026-09-21 |
Showing 20 of 8532. Sign in to see all of them.
Melanoma (3200) · Glioblastoma (2070) · Glioma (1449) · Brain Neoplasms (1006) · Astrocytoma (679) · Neuroblastoma (653) · Neoplasms (644) · Neuroendocrine Tumors (540) · Carcinoma, Non-Small-Cell Lung (498) · Gliosarcoma (487) · Central Nervous System Neoplasms (461) · Breast Neoplasms (422) · Oligodendroglioma (411) · Neoplasm Metastasis (395) · Sarcoma (377)
Neoplasms by Histologic Type (8506) · Neoplasms, Nerve Tissue (8483) · Neoplasms, Germ Cell and Embryonal (8476) · Neoplasms (7888) · Neoplasms by Site (5402) · Neoplasms, Glandular and Epithelial (5186) · Neoplasms, Neuroepithelial (4115) · Neuroendocrine Tumors (3997) · Skin and Connective Tissue Diseases (3379) · Nevi and Melanomas (3370) · Skin Diseases (3363) · Skin Neoplasms (3004) · Glioma (1882) · Nervous System Diseases (1726)
Temozolomide (672) · pembrolizumab (388) · Radiotherapy (381) · Nivolumab (366) · Cyclophosphamide (318) · Ipilimumab (302) · Bevacizumab (275) · Magnetic Resonance Spectroscopy (209) · Carboplatin (199) · aldesleukin (169) · Etoposide (154) · Cisplatin (138) · Radiation (138) · Interleukin-2 (130) · Vincristine (124)
National Cancer Institute (NCI) (555) · M.D. Anderson Cancer Center (214) · Memorial Sloan Kettering Cancer Center (180) · Children's Oncology Group (106) · Novartis Pharmaceuticals (104) · Bristol-Myers Squibb (92) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (90) · Duke University (85) · Mayo Clinic (84) · Dana-Farber Cancer Institute (72) · H. Lee Moffitt Cancer Center and Research Institute (65) · Hoffmann-La Roche (61) · St. Jude Children's Research Hospital (60) · Jonsson Comprehensive Cancer Center (59) · Merck Sharp & Dohme LLC (56)
United States (5006) · France (834) · Canada (632) · China (618) · Germany (580) · Italy (559) · United Kingdom (538) · Spain (524) · Australia (503) · Netherlands (420) · Switzerland (330) · Belgium (301) · Austria (191) · South Korea (186) · Israel (184)
Steven A Rosenberg, M.D. (31) · Steven A. Rosenberg, MD, PhD (27) · Stanislaw R. Burzynski, MD, PhD (19) · Annick Desjardins, MD, FRCPC (16) · Nader Sanai, MD (16)
PMID 31401903, PMID 36648215, PMID 25667295, PMID 24983357, PMID 39504507, PMID 22555974, PMID 23633099, PMID 34171339, PMID 37934000, PMID 38335473, PMID 19269895, PMID 22256804, PMID 25649350, PMID 26446943, PMID 31395089, PMID 32691060, PMID 32746839, PMID 36346112, PMID 38968568, PMID 39777725, PMID 15758009, PMID 23457002, PMID 23545055, PMID 23861247, PMID 24408395, PMID 24552317, PMID 24577748, PMID 25098701, PMID 25113840, PMID 27864013, PMID 29023494, PMID 29982805, PMID 30202085, PMID 30736858, PMID 32305010, PMID 32747469, PMID 33360855, PMID 34081125, PMID 34225229, PMID 34331515, PMID 34754076, PMID 35468680, PMID 36653848, PMID 37072349, PMID 37142373, PMID 37540556, PMID 39462179, PMID 39500789, PMID 40341199, PMID 40721981
2023 (66), U10CA098543 (49), 2019 (47), U10CA180886 (47), 2018 (43), 2016 (38), 2014 (33), P30CA033572 (30), 2009 (28), 2015 (27), 2017 (24), 2025 (23), P30CA015083 (23), P30CA016672 (23), U01CA062475 (23)